High-density lipoprotein cholesterol and residual cardiometabolic risk in metabolic syndrome

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Metabolic Syndrome Research

Background:

• Elevated low-density lipoprotein cholesterol (LDL-C) is a major cardiovascular disease (CVD) risk factor, and statin therapy reduces events but leaves significant residual risk.
• Low high-density lipoprotein cholesterol (HDL-C) is independently associated with increased CVD risk and is a component of metabolic syndrome.
• HDL cholesterol plays crucial roles in reverse cholesterol transport, endothelial protection, and possesses antioxidant, anti-inflammatory, antithrombotic, and antiapoptotic properties.

Purpose of the Study:

• To explore the therapeutic potential of increasing high-density lipoprotein cholesterol (HDL-C) concentrations for cardiovascular disease (CVD) risk reduction.
• To review traditional and novel pharmacotherapies aimed at increasing HDL-C levels.
• To evaluate emerging treatments including cholesteryl ester transfer protein (CETP) inhibitors and cannabinoid receptor 1 (CB1) antagonists.

Main Methods:

• Review of existing literature on lipid-lowering therapies and their impact on cardiovascular outcomes.
• Analysis of clinical trial data for novel agents targeting HDL-C.
• Examination of the mechanisms of action for traditional and emerging HDL-C-raising therapies.

Main Results:

• While statins effectively lower LDL-C, a substantial proportion of CVD cases and mortality persist.
• Emerging therapies, such as cholesteryl ester transfer protein (CETP) inhibitors, demonstrate potential for significant increases in HDL-C concentrations.
• Cannabinoid receptor 1 (CB1) antagonists, like rimonabant, have shown promise in increasing HDL-C and triglycerides, alongside weight loss.

Conclusions:

• Increasing HDL-C represents a promising therapeutic strategy to address residual cardiovascular risk, particularly in patients with metabolic syndrome.
• Novel pharmacotherapies targeting HDL-C, including CETP inhibition and CB1 antagonism, warrant further investigation for their efficacy in CVD prevention.
• Combined approaches addressing multiple risk factors, such as lipid levels and metabolic parameters, may be essential for comprehensive CVD management.